{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:19:28Z","timestamp":1778498368991,"version":"3.51.4"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100008883","name":"Nagoya City University","doi-asserted-by":"publisher","award":["2213037"],"award-info":[{"award-number":["2213037"]}],"id":[{"id":"10.13039\/501100008883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015293","name":"Policy-based Medical Services Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["JP 23K11922"],"award-info":[{"award-number":["JP 23K11922"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Area under the concentration\u2013time curve (AUC)\u2013guided dosing of vancomycin was introduced in a clinical setting; however, the target range of non\u2013steady-state AUCs, such as Day 1 AUC and Day 2 AUC, remains controversial. Therefore, we sought to determine pharmacokinetic parameter thresholds and identify independent risk factors associated with acute kidney injury (AKI) to establish a safe initial dosing design for vancomycin administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single-centre, retrospective, cohort study of hospitalized patients treated with vancomycin was conducted to determine the threshold of both non\u2013steady-state AUCs (Day 1 and 2 AUCs) and trough levels at the first blood sampling point (therapeutic drug monitoring, TDM). In addition, independent risk factors associated with AKI were evaluated using univariate and multivariate logistic regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The thresholds for predicting AKI were estimated as 456.6 mg\u00b7h\/L for AUC0-24h, 554.8 mg\u00b7h\/L for AUC24-48h, 1080.8 mg\u00b7h\/L for AUC0-48h and 14.0 \u03bcg\/mL for measured trough levels, respectively. In a multivariate analysis, Day 2 AUC\u200a\u2265\u200a554.8 mg\u00b7h\/L [adjusted odds ratio (OR), 57.16; 95% confidence interval (CI), 11.95\u2013504.05], piperacillin\/tazobactam (adjusted OR, 15.84; 95% CI, 2.73\u2013127.70) and diuretics (adjusted OR, 4.72; 95% CI, 1.13\u201321.01) were identified as risk factors for AKI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We identified thresholds for both AUCs in the non\u2013steady-state and trough levels at the first TDM. Our results highlight the importance of monitoring not only the AUC but also trough levels during vancomycin treatment to reduce the likelihood of AKI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae249","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T16:55:05Z","timestamp":1721408105000},"page":"2518-2527","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of target area under the concentration\u2013time curve of vancomycin in an initial dosing design: a retrospective cohort study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5814-6825","authenticated-orcid":false,"given":"Moeko","family":"Iida","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Horita","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Division of Infection Prevention and Control, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Asaoka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Division of Infection Prevention and Control, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University East Medical Center , 1-2-23 Wakamizu, Chikusa-ku, Nagoya, Aichi 464-8547 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Wachino","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University East Medical Center , 1-2-23 Wakamizu, Chikusa-ku, Nagoya, Aichi 464-8547 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toa","family":"Hirose","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Aichi Gakuin University , 1-100 Kusumoto-cho, Chikusa-ku, Nagoya, Aichi 464-8650 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Hisada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University West Medical Center , 1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi 462-8508 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Nagamizu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University West Medical Center , 1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi 462-8508 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Kawahara","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Aichi Gakuin University , 1-100 Kusumoto-cho, Chikusa-ku, Nagoya, Aichi 464-8650 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nagoya City University West Medical Center , 1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi 462-8508 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University East Medical Center , 1-2-23 Wakamizu, Chikusa-ku, Nagoya, Aichi 464-8547 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Infection Prevention and Control, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Furukawa-Hibi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]},{"name":"Department of Pharmacy, Nagoya City University Hospital , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"2024093023513329500_dkae249-B1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/cid\/ciz467","article-title":"60 plus years later and we are still trying to learn how to dose vancomycin","volume":"70","author":"Rodvold","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023513329500_dkae249-B4","doi-asserted-by":"publisher","first-page":"479730","DOI":"10.1155\/2013\/479730","article-title":"Epidemiology of acute kidney injury in the intensive care unit","volume":"2013","author":"Case","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"2024093023513329500_dkae249-B5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000337487","article-title":"Acute kidney injury and mortality in hospitalized patients","volume":"35","author":"Wang","year":"2012","journal-title":"Am J Nephrol"},{"key":"2024093023513329500_dkae249-B6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"key":"2024093023513329500_dkae249-B7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"Fern\u00e1ndez de Gatta","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"2024093023513329500_dkae249-B8","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcpt.13799","article-title":"Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: combined retrospective analyses of two real-world databases","volume":"131","author":"Chuma","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2024093023513329500_dkae249-B10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jgar.2021.07.018","article-title":"Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients","volume":"27","author":"Hashimoto","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2024093023513329500_dkae249-B11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024093023513329500_dkae249-B12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2024093023513329500_dkae249-B13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s13104-016-2252-7","article-title":"The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis","volume":"9","author":"Tongsai","year":"2016","journal-title":"BMC Res Notes"},{"key":"2024093023513329500_dkae249-B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"2024093023513329500_dkae249-B15","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B17","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","article-title":"Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological Society","volume":"71","author":"He","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FTD.0000000000000944","article-title":"Optimal practice for vancomycin therapeutic drug monitoring: position statement from the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"44","author":"Reuter","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2024093023513329500_dkae249-B19","doi-asserted-by":"publisher","first-page":"106812","DOI":"10.1016\/j.ijantimicag.2023.106812","article-title":"Should the trough concentration of vancomycin be abandoned in therapeutic drug monitoring? A multicentre, retrospective study of critically ill patients without any form of dialysis","volume":"61","author":"Yu","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023513329500_dkae249-B20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jiac.2020.10.014","article-title":"Comparison of trough concentration and area under the curve of vancomycin associated with the incidence of nephrotoxicity and predictors of a high trough level","volume":"27","author":"Suzuki","year":"2021","journal-title":"J Infect Chemother"},{"key":"2024093023513329500_dkae249-B21","doi-asserted-by":"publisher","first-page":"e01684-17","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023513329500_dkae249-B22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2024093023513329500_dkae249-B23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023513329500_dkae249-B24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program's retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"2024093023513329500_dkae249-B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.7","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2024093023513329500_dkae249-B26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/ki.1985.101","article-title":"Course of acute renal failure studied by a model of creatinine kinetics","volume":"27","author":"Moran","year":"1985","journal-title":"Kidney Int"},{"key":"2024093023513329500_dkae249-B27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12882-017-0552-3","article-title":"Diagnosis and outcomes of acute kidney injury using surrogate and imputation methods for missing preadmission creatinine values","volume":"18","author":"Bernier-Jean","year":"2017","journal-title":"BMC Nephrol"},{"key":"2024093023513329500_dkae249-B28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2024093023513329500_dkae249-B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.24595\/jjnp.7.1_25","article-title":"Survey of nephrotoxicity caused by the initial loading dose of vancomycin in patients with decreased renal function","volume":"7","author":"Asakawa","year":"2018","journal-title":"Jpn J Nephrol Pharmacother"},{"key":"2024093023513329500_dkae249-B30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024093023513329500_dkae249-B31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1620\/tjem.237.287","article-title":"Anemia is a risk factor for acute kidney injury and long-term mortality in critically ill patients","volume":"237","author":"Han","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"2024093023513329500_dkae249-B32","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"2024093023513329500_dkae249-B33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/FTD.0000000000001026","article-title":"Development and evaluation of a novel software program, SAKURA-TDM, for area under the concentration-time curve-guided vancomycin dosing: a short communication","volume":"45","author":"Horita","year":"2023","journal-title":"Ther Drug Monit"},{"key":"2024093023513329500_dkae249-B34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther Drug Monit"},{"key":"2024093023513329500_dkae249-B35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2024093023513329500_dkae249-B36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2024093023513329500_dkae249-B37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"2024093023513329500_dkae249-B38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1&lt;32::AID-CNCR2820030106&gt;3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2024093023513329500_dkae249-B39","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/jep.12767","article-title":"Usefulness of a decision tree model for the analysis of adverse drug reactions: evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure","volume":"23","author":"Imai","year":"2017","journal-title":"J Eval Clin Pract"},{"key":"2024093023513329500_dkae249-B40","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1111\/bcp.15252","article-title":"Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity","volume":"88","author":"Imai","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024093023513329500_dkae249-B41","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2024093023513329500_dkae249-B42","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"57","author":"Moise","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"2024093023513329500_dkae249-B43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/antibiotics11010096","article-title":"Validation of vancomycin area under the concentration-time curve estimation by the Bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections","volume":"11","author":"Ueda","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024093023513329500_dkae249-B44","doi-asserted-by":"publisher","first-page":"e02535-16","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023513329500_dkae249-B45","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/jac\/dkz167","article-title":"Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model","volume":"74","author":"Avedissian","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024093023513329500_dkae249-B46","doi-asserted-by":"publisher","first-page":"ofaa538","DOI":"10.1093\/ofid\/ofaa538","article-title":"Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 study","volume":"7","author":"Liu","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024093023513329500_dkae249-B47","doi-asserted-by":"publisher","first-page":"ofab651","DOI":"10.1093\/ofid\/ofab651","article-title":"Associations between vancomycin exposure and acute kidney injury within the recommended area under the curve therapeutic exposure range among patients with methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"9","author":"Lodise","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024093023513329500_dkae249-B48","doi-asserted-by":"publisher","first-page":"106234","DOI":"10.1016\/j.ijantimicag.2020.106234","article-title":"Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury","volume":"57","author":"Muklewicz","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023513329500_dkae249-B49","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/jac\/dkad333","article-title":"Comparison of the incidence of vancomycin-associated nephrotoxicity following the change from trough-guided dosing to AUC-guided doing using trough-only data","volume":"78","author":"Yamada","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2518\/59460068\/dkae249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2518\/59460068\/dkae249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T23:51:42Z","timestamp":1727740302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/10\/2518\/7717182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae249","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,19]]}}}